From Nasdaq: 2025-05-26 15:00:00

Tempus AI and Butterfly Network are leading AI-driven healthcare companies revolutionizing diagnostics. Tempus AI excels in precision oncology, while Butterfly Network is changing point-of-care imaging. Both companies are integrating AI to make advanced diagnostics more accessible. Over the past year, their shares surged 55.4% and 114.8%, respectively, outperforming the industry and S&P 500.

Tempus AI shows promise with revenue growth, margin expansion leading to economies of scale, and positive EBITDA on the horizon. Strategic AI partnerships, strong contract backlog and clinical integration provide financial stability. Butterfly Network’s strong start to FY2025, diversified product portfolio, international expansion, and financial improvements position it well for growth.

Comparing valuations, Butterfly Network appears attractively valued compared to Tempus AI. Analysts project a better upside for Butterfly Network, making it a more compelling near-term investment. With a Zacks Rank #2 (Buy) and improving financials, Butterfly Network stands out as the more attractive option for investors at present.



Read more at Nasdaq: Tempus AI vs. Butterfly: Which AI Health Tech Stock is the Better Buy?